The demographic and clinical characteristics of each group are shown inTable 1. increased significantly from baseline through post-dose 1 to post-dose 2 in Linaclotide all three groups. At the post-dose 1, the anti-RBD IgG and neutralizing antibody levels were significantly lower in malignancy patients than in healthy controls. However, by post-dose 2, the seropositivity of anti-RBD IgG and neutralizing antibodies uniformly reached 100% across all groups, with no significant disparity in antibody levels among the three groups. Moreover, the antibody titers were not significantly different between patients with a vaccine and chemotherapy interval of more than 14 days or those with less than 14 days. This study exhibited that after second doses of mRNA COVID-19 vaccines, humoral immune responses in patients receiving chemotherapy were comparable to those of healthy controls, regardless of whether the purpose of the anti-cancer treatment was palliative or adjuvant. Furthermore, the timing of vaccination did not affect the level of humoral immunity after the second vaccination. Keywords:COVID-19, Vaccination, Neoplasms, mRNA == INTRODUCTION == Patients with malignancy have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general populace.1Owing to this increased risk, patients with malignancy have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, data around the COVID-19 vaccine in malignancy populations are still limited. In patients with solid cancers, some studies have found that Rabbit polyclonal to HIBCH COVID-19 vaccines have comparable immunogenicity relative to the general populace,2,3,4but other studies have exhibited lower immunogenicity in malignancy patients relative to that in healthy controls.5,6,7Obtaining consistent results for COVID-19 vaccine-related immunogenicity in patients with solid cancers might be difficult because of variations in several factors, such as malignancy types, disease status, and anticancer therapy. In terms of therapeutic intention, chemotherapy can be divided into two main groups: adjuvant and palliative. Adjuvant chemotherapy is designed to minimize recurrence by eradicating residual malignancy following main interventions such as surgery. As a result, this modality is usually administered for any predetermined period of time. Conversely, palliative chemotherapy is used to reduce tumor size with the goal of relieving symptoms in stages that are considered incurable. Such treatment is usually often characterized by a relatively high tumor burden and prolonged chemotherapy duration. Consequently, patients undergoing palliative chemotherapy are postulated to have more impaired immune function. To date, few studies have compared immunogenicity based on how long chemotherapy lasted or how the malignancy progressed.8Thus, we undertook a study to investigate potential differences in vaccine efficacy between patients undergoing palliative chemotherapy and those receiving adjuvant chemotherapy. Distinct from standard vaccines, COVID-19 vaccines are recommended to be given during active chemotherapy regardless of when the chemotherapeutic brokers are administered.9However, you will find no studies that have evaluated the optimal timing of COVID-19 vaccination in malignancy patients. In addressing this space, we investigated the effect of vaccination timing on vaccine efficacy in patients undergoing active chemotherapy. == MATERIALS AND METHODS Linaclotide == == 1. Participants and study design == This prospective study was conducted at three malignancy centers and one general hospital in South Korea from July 2021 through February 2022. This study was approved by the Institutional Review Table of Chonnam National University Hwasun Hospital (CNUHH-2021-124), Chonnam National University Bitgoeul Hospital (CNUBH-2021-014), Chungnam National University Sejong Hospital (CNUSH 2021-07-013), Linaclotide and Soonchunhyang University or college Hospital Cheonan (SUCH 2021-07-039). All participants gave their consent to participate by signing the informed consent form. Three groups of participants were enrolled: control individuals without any malignancy or other known immunological disorders, patients with solid cancers undergoing adjuvant chemotherapy, and patients with solid cancers undergoing palliative chemotherapy. Adjuvant chemotherapy was defined as chemotherapy given additionally after attempted curative surgery. Palliative chemotherapy was defined as chemotherapy given in the non-curative setting to optimize symptom control, improve quality of life, and extend survival. Cancer patients who received their most recent chemotherapy administration within 4 weeks of mRNA vaccination were enrolled. In all groups, individuals with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contamination were excluded. After enrollment, participants received two doses of the COVID-19 mRNA vaccines (0.3 mL of BNT162b2 or 0.5 mL of mRNA-1273) 3 to 6 weeks apart. General public healthcare system government bodies designed the vaccination program; hence, we could not control the vaccination interval or the timing of vaccine administration within the anticancer therapy routine. Three blood samples were obtained from each participant: the first sample before vaccination (baseline), the second sample at 2 to 4 weeks after the first vaccination (post-dose 1), and the third sample at 2 to 4 weeks after the second vaccination (post-dose 2) (Fig. 1). == FIG. 1. Study design and schematic diagram of sample collection before and after vaccination.*One patient in the adjuvant group was enrolled after the first vaccination.